Literature DB >> 21814341

MCT oil-based diet reverses hypertrophic cardiomyopathy in a patient with very long chain acyl-coA dehydrogenase deficiency.

Muhammad Ali Pervaiz1, Fran Kendal, Madhuri Hegde, Rani H Singh.   

Abstract

Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is one of the genetic defects of mitochondrial fatty acid beta-oxidation presenting in early infancy or childhood. If undiagnosed and untreated, VLCAD deficiency may be fatal, secondary to cardiac involvement. We assessed the effect of replacing part of the fat in the diet of a 2 ½-month-old male infant, who was diagnosed with VLCAD deficiency,with medium-chain triglyceride (MCT) oil and essential fats. The patient presented with vomiting, dehydration, and was found to have persistent elevation of liver function tests, hepatomegaly, pericardial and pleural effusion, right bundle branch block, and biventricular hypertrophy. Because of the cardiomyopathy, hepatomegaly, and an abnormal acylcarnitine profile and urine organic acids, he was suspected of having VLCAD deficiency. This was confirmed on acyl-coA dehydrogenase, very long chain (ACADVL) gene analysis. He was begun on an MCT oil-based formula with added essential fatty acids, uncooked cornstarch (around 1 year of age), and frequent feeds. By 7 months of age, cardiomyopathy had reversed and by 18 months of age, all cardiac medications were discontinued and hypotonia had improved such that physical therapy was no longer required. At 5 years of age, he is at the 50(th) percentile for height and weight along with normal development. Pediatricians need to be aware about the basic pathophysiology of the disease and the rationale behind its treatment as more patients are being diagnosed because of expansion of newborn screen. The use of MCT oil as a medical intervention for treatment of VLCAD deficiency remains controversial mostly because of lack of clear phenotype-genotype correlations, secondary to the genetic heterogeneity of the mutations. Our case demonstrated the medical necessity of MCT oil-based nutritional intervention and the need for the further research for the development of specific guidelines to improve the care of these patients.

Entities:  

Keywords:  Cardiomyopathy; MCT oil; carnitine; inborn error of metabolism; very long chain acyl-CoA dehydrogenase deficiency

Year:  2011        PMID: 21814341      PMCID: PMC3144685          DOI: 10.4103/0971-6866.82190

Source DB:  PubMed          Journal:  Indian J Hum Genet        ISSN: 1998-362X


  16 in total

1.  Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop.

Authors:  U Spiekerkoetter; M Lindner; R Santer; M Grotzke; M R Baumgartner; H Boehles; A Das; C Haase; J B Hennermann; D Karall; H de Klerk; I Knerr; H G Koch; B Plecko; W Röschinger; K O Schwab; D Scheible; F A Wijburg; J Zschocke; E Mayatepek; U Wendel
Journal:  J Inherit Metab Dis       Date:  2009-04-28       Impact factor: 4.982

2.  Management of fatty acid oxidation disorders: a survey of current treatment strategies.

Authors:  Java O Solis; Rani H Singh
Journal:  J Am Diet Assoc       Date:  2002-12

3.  Clinical and molecular heterogeneity in very-long-chain acyl-coenzyme A dehydrogenase deficiency.

Authors:  R Pons; P Cavadini; S Baratta; F Invernizzi; E Lamantea; B Garavaglia; F Taroni
Journal:  Pediatr Neurol       Date:  2000-02       Impact factor: 3.372

4.  Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death.

Authors:  A Mathur; H F Sims; D Gopalakrishnan; B Gibson; P Rinaldo; J Vockley; G Hug; A W Strauss
Journal:  Circulation       Date:  1999-03-16       Impact factor: 29.690

5.  Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency.

Authors:  B S Andresen; S Olpin; B J Poorthuis; H R Scholte; C Vianey-Saban; R Wanders; L Ijlst; A Morris; M Pourfarzam; K Bartlett; E R Baumgartner; J B deKlerk; L D Schroeder; T J Corydon; H Lund; V Winter; P Bross; L Bolund; N Gregersen
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

6.  Acute, severe cardiomyopathy as main symptom of late-onset very long-chain acyl-coenzyme A dehydrogenase deficiency.

Authors:  R Parini; F Menni; B Garavaglia; V Fesslova; D Melotti; M L Massone; E Lamantea; M Rimoldi; P Vizziello; R Gatti
Journal:  Eur J Pediatr       Date:  1998-12       Impact factor: 3.183

7.  Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients.

Authors:  T Aoyama; M Souri; S Ushikubo; T Kamijo; S Yamaguchi; R I Kelley; W J Rhead; K Uetake; K Tanaka; T Hashimoto
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

8.  Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency.

Authors:  Pascal Laforêt; Cécile Acquaviva-Bourdain; Odile Rigal; Michèle Brivet; Isabelle Penisson-Besnier; Brigitte Chabrol; Denys Chaigne; Odile Boespflug-Tanguy; Cécile Laroche; Anne-Laure Bedat-Millet; Anthony Behin; Isabelle Delevaux; Anne Lombès; Brage S Andresen; Bruno Eymard; Christine Vianey-Saban
Journal:  Neuromuscul Disord       Date:  2009-03-26       Impact factor: 4.296

9.  Compared effects of missense mutations in Very-Long-Chain Acyl-CoA Dehydrogenase deficiency: Combined analysis by structural, functional and pharmacological approaches.

Authors:  Stéphanie Gobin-Limballe; Ryan P McAndrew; Fatima Djouadi; Jung-Ja Kim; Jean Bastin
Journal:  Biochim Biophys Acta       Date:  2010-01-12

10.  A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency.

Authors:  Georgianne L Arnold; Johan Van Hove; Debra Freedenberg; Arnold Strauss; Nicola Longo; Barbara Burton; Cheryl Garganta; Can Ficicioglu; Stephen Cederbaum; Cary Harding; Richard G Boles; Dietrich Matern; Pranesh Chakraborty; Annette Feigenbaum
Journal:  Mol Genet Metab       Date:  2009-01-20       Impact factor: 4.797

View more
  7 in total

1.  Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States.

Authors:  Marcus J Miller; Lindsay C Burrage; James B Gibson; Meghan E Strenk; Edward J Lose; David P Bick; Sarah H Elsea; V Reid Sutton; Qin Sun; Brett H Graham; William J Craigen; Victor Wei Zhang; Lee-Jun C Wong
Journal:  Mol Genet Metab       Date:  2015-09-02       Impact factor: 4.797

Review 2.  Fatty acid oxidation disorders.

Authors:  J Lawrence Merritt; Marie Norris; Shibani Kanungo
Journal:  Ann Transl Med       Date:  2018-12

3.  Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.

Authors:  Sara Tucci; Ulrich Floegel; Frauke Beermann; Sidney Behringer; Ute Spiekerkoetter
Journal:  J Lipid Res       Date:  2016-11-24       Impact factor: 5.922

Review 4.  Very long-chain acyl-CoA dehydrogenase (VLCAD-) deficiency-studies on treatment effects and long-term outcomes in mouse models.

Authors:  Sara Tucci
Journal:  J Inherit Metab Dis       Date:  2017-02-28       Impact factor: 4.982

5.  Successful Treatment of Cardiomyopathy due to Very Long-Chain Acyl-CoA Dehydrogenase Deficiency: First Case Report from Oman with Literature Review.

Authors:  Sharef Waadallah Sharef; Khalfan Al-Senaidi; Surendra Nath Joshi
Journal:  Oman Med J       Date:  2013-09

Review 6.  Medium chain triglycerides (MCT) formulas in paediatric and allergological practice.

Authors:  Ewa Łoś-Rycharska; Zuzanna Kieraszewicz; Mieczysława Czerwionka-Szaflarska
Journal:  Prz Gastroenterol       Date:  2016-07-20

7.  Treatment of VLCAD-Deficient Patient Fibroblasts with Peroxisome Proliferator-Activated Receptor δ Agonist Improves Cellular Bioenergetics.

Authors:  Olivia M D'Annibale; Yu Leng Phua; Clinton Van't Land; Anuradha Karunanidhi; Alejandro Dorenbaum; Al-Walid Mohsen; Jerry Vockley
Journal:  Cells       Date:  2022-08-24       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.